Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 70 articles:
HTML format



Single Articles


    December 2021
  1. ZHAO JL, Fizazi K, Saad F, Chi KN, et al
    The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial.
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-1090.
    PubMed     Abstract available


  2. BERCHUCK JE, Baca SC, McClure HM, Korthauer K, et al
    Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis.
    Clin Cancer Res. 2021 Dec 14. pii: 1078-0432.CCR-21-3762.
    PubMed     Abstract available


    November 2021
  3. PENG S, Hu P, Xiao YT, Lu W, et al
    Single-cell analysis reveals EP4 as a target for restoring T cell infiltration and sensitizing prostate cancer to immunotherapy.
    Clin Cancer Res. 2021 Nov 5. pii: 1078-0432.CCR-21-0299.
    PubMed     Abstract available


  4. AL-UBAIDI FLT, Schultz N, Loseva O, Egevad L, et al
    Editor's Note: Castration Therapy Results in Decreased Ku70 Levels in Prostate Cancer.
    Clin Cancer Res. 2021;27:6066.
    PubMed    


    October 2021
  5. DORFF TB, Narayan V, Forman SJ, Zang PD, et al
    Novel Redirected T Cell Immunotherapies for Advanced Prostate Cancer.
    Clin Cancer Res. 2021 Oct 21. pii: 1078-0432.CCR-21-1483.
    PubMed     Abstract available


  6. STOPSACK KH, Nandakumar S, Arora K, Nguyen B, et al
    Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors.
    Clin Cancer Res. 2021 Oct 19. pii: 1078-0432.CCR-21-2577.
    PubMed     Abstract available


  7. LOEHR A, Patnaik A, Campbell D, Shapiro J, et al
    Response to rucaparib in BRCA-mutant metastatic castration-resistant prostate cancer identified by genomic testing in the TRITON2 study.
    Clin Cancer Res. 2021 Oct 1. pii: 1078-0432.CCR-21-2199.
    PubMed     Abstract available


    September 2021
  8. ZHANG H, Orme JJ, Abraha F, Stish BJ, et al
    Phase II evaluation of Stereotactic Ablative Radiotherapy (SABR) and immunity in (11)C-Choline-PET/CT-identified oligometastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-2510.
    PubMed     Abstract available


  9. MIZUNO K, Sumiyoshi T, Okegawa T, Terada N, et al
    Clinical impact of detecting low-frequency variants in cell-free DNA on treatment of castration-resistant prostate cancer.
    Clin Cancer Res. 2021 Sep 15. pii: 1078-0432.CCR-21-2328.
    PubMed     Abstract available


    August 2021
  10. MOSTAGHEL EA, Marck BT, Kolokythas O, Chew F, et al
    Circulating and intra-tumoral adrenal androgens correlate with response to abiraterone in men with castration resistant prostate cancer.
    Clin Cancer Res. 2021 Aug 18. pii: 1078-0432.CCR-21-1819.
    PubMed     Abstract available


    July 2021
  11. MURTOLA TJ, Siltari A
    Statins for prostate cancer: when and how much?
    Clin Cancer Res. 2021 Jul 19. pii: 1078-0432.CCR-21-1891.
    PubMed     Abstract available


  12. SARKER D, Dawson NA, Aparicio AM, Dorff TB, et al
    A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kbeta inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2021 Jul 19. pii: 1078-0432.CCR-21-1115.
    PubMed     Abstract available


    June 2021
  13. TURNER PG, Jain S, Cole A, Grey A, et al
    Toxicity and efficacy of concurrent androgen deprivation therapy, pelvic radiotherapy, and radium-223 in patients with de-novo metastatic hormone sensitive prostate cancer.
    Clin Cancer Res. 2021 Jun 29. pii: 1078-0432.CCR-21-0685.
    PubMed     Abstract available


  14. CALAGUA C, Ficial M, Jansen CS, Hirz T, et al
    A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.
    Clin Cancer Res. 2021 Jun 24. pii: 1078-0432.CCR-21-0121.
    PubMed     Abstract available


  15. TANG Z, Pilie PG, Geng C, Manyam GC, et al
    ATR inhibitor-induced CDK1-SPOP axis destabilizes PD-L1 and enhances cytotoxicity in prostate cancer.
    Clin Cancer Res. 2021 Jun 24. pii: 1078-0432.CCR-21-1010.
    PubMed     Abstract available


  16. KIM DH, Sun D, Storck WK, Welker Leng KR, et al
    BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
    Clin Cancer Res. 2021 Jun 18. pii: 1078-0432.CCR-20-4968.
    PubMed     Abstract available


  17. SMITH MR, Thomas S, Gormley M, Chowdhury S, et al
    Blood Biomarker Landscape in Patients with High-Risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.
    Clin Cancer Res. 2021 Jun 10. pii: 1078-0432.CCR-21-0358.
    PubMed     Abstract available


  18. FONG L, Morris MJ, Sartor O, Higano CS, et al
    A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2021 Jun 9. pii: 1078-0432.CCR-21-0063.
    PubMed     Abstract available


  19. ANNALA M, Taavitsainen S, Khalaf DJ, Vandekerkhove G, et al
    Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition.
    Clin Cancer Res. 2021 Jun 3. pii: 1078-0432.CCR-21-1625.
    PubMed     Abstract available


  20. HAWKEY NM, Armstrong AJ
    Liquid Biopsy: It's the Bloody Truth!
    Clin Cancer Res. 2021;27:2961-2963.
    PubMed     Abstract available


    May 2021
  21. HAMMER S, Schlicker A, Zitzmann-Kolbe S, Baumgart S, et al
    Darolutamide potentiates the antitumor efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC) by a dual mode-of-action in prostate cancer models.
    Clin Cancer Res. 2021 May 25. pii: 1078-0432.CCR-21-0342.
    PubMed     Abstract available


  22. MUNN LL, Stylianopoulos T, Jain NK, Hardin CC, et al
    Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer.
    Clin Cancer Res. 2021;27:2706-2711.
    PubMed     Abstract available


  23. KAWAMOTO K, Okino ST, Place RF, Urakami S, et al
    Editor's Note: Epigenetic Modifications of RASSF1A Gene through Chromatin Remodeling in Prostate Cancer.
    Clin Cancer Res. 2021;27:2665.
    PubMed    


    April 2021
  24. TRUE LD, Chen DL
    How accurately does PSMA inhibitor 18F-DCFPyL-PET-CT image prostate cancer?
    Clin Cancer Res. 2021 Apr 23. pii: 1078-0432.CCR-21-0749.
    PubMed     Abstract available


  25. PRIVE BM, Peters SMB, Muselaers CHJ, van Oort IM, et al
    Lutetium-177-PSMA-617 in low-volume hormone sensitive metastatic prostate cancer, a prospective pilot study.
    Clin Cancer Res. 2021 Apr 21. pii: 1078-0432.CCR-20-4298.
    PubMed     Abstract available


  26. MCKAY RR, Kwak L, Crowdis J, Sperger JM, et al
    Phase 2 multicenter study of enzalutamide in metastatic castration resistant prostate cancer to identify mechanisms driving resistance.
    Clin Cancer Res. 2021 Apr 13. pii: 1078-0432.CCR-20-4616.
    PubMed     Abstract available


    March 2021
  27. PACHYNSKI RK, Kim E, Miheecheva N, Kotlov N, et al
    Single cell spatial proteomic revelations on the multiparametric MRI heterogeneity of clinically significant prostate cancer.
    Clin Cancer Res. 2021 Mar 26. pii: 1078-0432.CCR-20-4217.
    PubMed     Abstract available


  28. VARDAKI I, Corn P, Gentile E, Song JH, et al
    Radium 223 treatment increase immune checkpoint expression in extracellular vesicles from the metastatic prostate cancer bone microenvironment.
    Clin Cancer Res. 2021 Mar 22. pii: 1078-0432.CCR-20-4790.
    PubMed     Abstract available


  29. PALMBOS PL, Daignault-Newton S, Tomlins SA, Agarwal N, et al
    A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone Sensitive Prostate Cancer (mHSPC).
    Clin Cancer Res. 2021 Mar 16. pii: 1078-0432.CCR-21-0024.
    PubMed     Abstract available


  30. FREEDLAND SJ, Allen J, Jarman A, Oyekunle T, et al
    Correction: A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2).
    Clin Cancer Res. 2021;27:1823.
    PubMed    


  31. KAMAT NV, Yu EY, Lee JK
    BiTE-ing into prostate cancer with bispecific T cell engagers.
    Clin Cancer Res. 2021 Mar 11. pii: 1078-0432.CCR-21-0355.
    PubMed     Abstract available


    February 2021
  32. MORRIS MJ, Rowe SP, Gorin MA, Saperstein L, et al
    Diagnostic Performance of (18)F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase 3, Multicenter Study.
    Clin Cancer Res. 2021 Feb 23. pii: 1078-0432.CCR-20-4573.
    PubMed     Abstract available


  33. PETRYLAK DP, Loriot Y, Shaffer D, Braiteh F, et al
    Safety and Clinical Activity of Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer: a Phase I Study.
    Clin Cancer Res. 2021 Feb 10. pii: 1078-0432.CCR-20-1981.
    PubMed     Abstract available


  34. TUKACHINSKY H, Madison RW, Chung JH, Gjoerup O, et al
    Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms.
    Clin Cancer Res. 2021 Feb 8. pii: 1078-0432.CCR-20-4805.
    PubMed     Abstract available


  35. LIANG Y, Jeganathan S, Marastoni S, Sharp A, et al
    Emergence of Enzalutamide resistance in prostate cancer is associated with BCL-2 and IKKB dependencies.
    Clin Cancer Res. 2021 Feb 4. pii: 1078-0432.CCR-20-3260.
    PubMed     Abstract available


    January 2021
  36. DEEGEN P, Thomas O, Nolan-Stevaux O, Li S, et al
    The PSMA Targeting Half-Life Extended BiTE((R)) Therapy AMG 160 Has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2021 Jan 27. pii: 1078-0432.CCR-20-3725.
    PubMed     Abstract available


  37. GOLDKORN A, Tangen CM, Plets M, Morrison GJ, et al
    Baseline circulating tumor cell count as a prognostic marker of PSA response and disease progression in metastatic castrate sensitive prostate cancer (SWOG S1216).
    Clin Cancer Res. 2021 Jan 26. pii: 1078-0432.CCR-20-3587.
    PubMed     Abstract available


  38. PAN W, Zhang Z, Kimball H, Qu F, et al
    Abiraterone acetate induces CREB1 phosphorylation and enhances the function of the CBP-p300 complex, leading to resistance in prostate cancer cells.
    Clin Cancer Res. 2021 Jan 25. pii: 1078-0432.CCR-20-4391.
    PubMed     Abstract available


  39. MARSHALL CH, Fu W, Wang H, Park JC, et al
    Randomized phase II trial of sipuleucel-T with or without radium-223 in men with bone-metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2021 Jan 15. pii: 1078-0432.CCR-20-4476.
    PubMed     Abstract available


  40. RESCIGNO P, Gurel B, Pereira R, Crespo M, et al
    Characterizing CDK12-Mutated Prostate Cancers.
    Clin Cancer Res. 2021;27:566-574.
    PubMed     Abstract available


  41. VEACH D, Storey CM, Lueckerath K, Braun K, et al
    PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates.
    Clin Cancer Res. 2021 Jan 13. pii: 1078-0432.CCR-20-3614.
    PubMed     Abstract available


    December 2020
  42. WANG S, Li J, Hua J, Su Y, et al
    Molecular imaging of prostate cancer targeting CD46 using immunoPET.
    Clin Cancer Res. 2020 Dec 8. pii: 1078-0432.CCR-20-3310.
    PubMed     Abstract available


    November 2020
  43. LOTAN TL, Antonarakis ES
    CDK12 Deficiency and the Immune Microenvironment in Prostate Cancer.
    Clin Cancer Res. 2020 Nov 16. pii: 1078-0432.CCR-20-3877.
    PubMed     Abstract available


  44. DELUCIA DC, Cardillo TM, Ang LS, Labrecque MP, et al
    Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer.
    Clin Cancer Res. 2020 Nov 16. pii: 1078-0432.CCR-20-3396.
    PubMed     Abstract available


    October 2020
  45. AWASTHI S, Berglund AE, Abraham-Miranda J, Rounbehler RJ, et al
    Comparative genomics reveals distinct immune-oncologic pathways in African American men with prostate cancer.
    Clin Cancer Res. 2020 Oct 9. pii: 1078-0432.CCR-20-2925.
    PubMed     Abstract available


  46. KARZAI F, Walker SM, Wilkinson S, Madan RA, et al
    Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-Risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is predictive of therapeutic response.
    Clin Cancer Res. 2020 Oct 6. pii: 1078-0432.CCR-20-2344.
    PubMed     Abstract available


    September 2020
  47. CHEN WS, Haynes WA, Waitz R, Kamath K, et al
    Autoantibody landscape in patients with advanced prostate cancer.
    Clin Cancer Res. 2020 Sep 23. pii: 1078-0432.CCR-20-1966.
    PubMed     Abstract available


  48. TRIPATHI A, Supko JG, Gray KP, Melnick Z, et al
    Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study of Concurrent Enzalutamide and Crizotinib.
    Clin Cancer Res. 2020 Sep 17. pii: 1078-0432.CCR-20-2306.
    PubMed     Abstract available


  49. GAO AC, Armstrong CM, Liu C, Liu L, et al
    Steroid sulfatase stimulates intracrine androgen synthesis and is a therapeutic target for advanced prostate cancer.
    Clin Cancer Res. 2020 Sep 14. pii: 1078-0432.CCR-20-1682.
    PubMed     Abstract available


  50. BORDINI J, Morisi F, Elia AR, Santambrogio P, et al
    Iron induces cell death and strengthens the efficacy of anti-androgen therapy in prostate cancer models.
    Clin Cancer Res. 2020 Sep 14. pii: 1078-0432.CCR-20-3182.
    PubMed     Abstract available


    August 2020
  51. MUNIYAN S, Rachagani S, Parte S, Halder S, et al
    Sildenafil potentiates the therapeutic efficacy of docetaxel in advanced prostate cancer by stimulating NO-cGMP signaling.
    Clin Cancer Res. 2020 Aug 26. pii: 1078-0432.CCR-20-1569.
    PubMed     Abstract available


  52. AUTIO KA, Klebanoff CA, Schaer DA, Kauh JS, et al
    Immunomodulatory Activity of a Colony-Stimulating Factor-1 Receptor Inhibitor in Patients With Advanced Refractory Breast or Prostate Cancer: A Phase 1 Study.
    Clin Cancer Res. 2020 Aug 26. pii: 1078-0432.CCR-20-0855.
    PubMed     Abstract available


    July 2020
  53. SHENDEROV E, Antonarakis ES
    Reimagining vaccines for prostate cancer: Back to the future.
    Clin Cancer Res. 2020 Jul 31. pii: 1078-0432.CCR-20-2257.
    PubMed     Abstract available


  54. GUAN X, Sun D, Lu E, Urrutia JA, et al
    Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2020 Jul 29. pii: 1078-0432.CCR-19-2303.
    PubMed     Abstract available


  55. PARK SY, Na SJ, Kumar M, Mosci C, et al
    Clinical evaluation of (4S)-4-(3-[(18)F]Fluoropropyl)-L-glutamate ((18)F-FSPG) for PET/CT imaging in patients with newly diagnosed and recurrent prostate cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-0644.
    PubMed     Abstract available


  56. AGGARWAL RR, Schweizer MT, Nanus DM, Pantuck AJ, et al
    A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-1707.
    PubMed     Abstract available


  57. KAUR H, Salles DC, Murali S, Hicks JL, et al
    Genomic and Clinical-Pathologic Characterization of ATM-deficient Prostate Cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-0764.
    PubMed     Abstract available


  58. HINTZ HM, Gallant JP, Vander Griend DJ, Coleman I, et al
    Imaging Fibroblast Activation Protein Alpha improves diagnosis of metastatic Prostate Cancer with Positron Emission Tomography.
    Clin Cancer Res. 2020 Jul 7. pii: 1078-0432.CCR-20-1358.
    PubMed     Abstract available


    June 2020
  59. PALANISAMY N, Yang J, Shepherd PDA, Li-Ning-Tapia EM, et al
    The MD Anderson prostate cancer patient-derived xenograft series (MDA PCa PDX) captures the molecular landscape of prostate cancer and facilitates marker-driven therapy development.
    Clin Cancer Res. 2020 Jun 23. pii: 1078-0432.CCR-20-0479.
    PubMed     Abstract available


  60. PEREZ-RUIXO C, Ackaert O, Ouellet D, Chien C, et al
    Efficacy and safety exposure-response relationships of apalutamide in patients with non-metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2020 Jun 19. pii: 1078-0432.CCR-20-1041.
    PubMed     Abstract available


  61. RAVI KUMAR AS, Hofman MS
    Mechanistic Insights for Optimizing PSMA Radioligand Therapy.
    Clin Cancer Res. 2020;26:2774-2776.
    PubMed     Abstract available


  62. CURRENT K, Meyer C, Magyar CE, Mona CE, et al
    Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity.
    Clin Cancer Res. 2020;26:2946-2955.
    PubMed     Abstract available


  63. WANG B, Liu C, Wei Y, Meng J, et al
    A prospective trial of (68)Ga-PSMA and (18)F-FDG PET/CT in nonmetastatic prostate cancer patients with an early PSA progression during castration.
    Clin Cancer Res. 2020 Jun 11. pii: 1078-0432.CCR-20-0587.
    PubMed     Abstract available


  64. KYRIAKOPOULOS CE, Eickhoff J, Ferrari AC, Schweizer MT, et al
    Multicenter Phase 1 Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer.
    Clin Cancer Res. 2020 Jun 8. pii: 1078-0432.CCR-20-0945.
    PubMed     Abstract available


    May 2020
  65. POSADAS EM, Chi KN, de Wit R, de Jonge MJA, et al
    Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase 1b Study.
    Clin Cancer Res. 2020 May 4. pii: 1078-0432.CCR-19-3402.
    PubMed     Abstract available


    April 2020
  66. MALIHI PD, Graf RP, Rodriguez A, Ramesh N, et al
    Single-cell circulating tumor cell analysis reveals genomic instability as a distinctive feature of aggressive prostate cancer.
    Clin Cancer Res. 2020 Apr 27. pii: 1078-0432.CCR-19-4100.
    PubMed     Abstract available


  67. MANDIGO AC, Knudsen KE
    Double Trouble: Concomitant RB1 and BRCA2 Depletion Evokes Aggressive Phenotypes.
    Clin Cancer Res. 2020;26:1784-1786.
    PubMed     Abstract available


  68. BRAVE M, Weinstock C, Brewer JR, Chi DC, et al
    An FDA Review of Drug Development in Non-Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2020 Apr 13. pii: 1078-0432.CCR-19-3835.
    PubMed     Abstract available


    March 2020
  69. SOKOLOVA AO, Yu EY, Cheng HH
    Honing in on PARPi response in Prostate Cancer: from HR pathway- to gene-by-gene granularity.
    Clin Cancer Res. 2020 Mar 31. pii: 1078-0432.CCR-20-0707.
    PubMed     Abstract available


  70. STOPSACK KH, Nandakumar S, Wibmer AG, Haywood S, et al
    Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer.
    Clin Cancer Res. 2020 Mar 27. pii: 1078-0432.CCR-20-0168.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: